CIK/DC-CIK cell therapy plus chemotherapy improves overall survival in patients with gastric cancer
This meta-analysis evaluated the efficacy of CIK/DC-CIK cell therapy combined with chemotherapy compared to chemotherapy alone for patients with gastric cancer. The analysis included data from 22 trials involving a total of 2,149 patients, with 1,047 patients included in the overall survival (OS) analysis.
The primary finding was a significant benefit in overall survival for the combination therapy group compared to the chemotherapy-only group. The meta-analysis reported a hazard ratio of 0.60 (95% CI 0.48 to 0.75). Secondary outcomes such as disease-free survival, progression-free survival, and T-lymphocyte subsets were also assessed but specific pooled values were not provided in the summary data.
A limitation noted is that only 13 of the 22 trials were included in the quantitative synthesis. Safety data for adverse events were summarized descriptively, though specific rates for serious adverse events or treatment discontinuations were not reported. Clinical application should consider these results as an association from a meta-analysis of clinical trials.